Radnor’s Adapt Pharma, maker of the Narcan Nasal Spray used for the emergency treatment of opioid overdose, has partnered with Aptar Pharma, a leader in the global dispensing systems industry, to provide Narcan’s delivery system and regulatory support.

According to Jim Butschli, editor of Healthcare Packaging, Aptar Pharma referred to Narcan as “the first U.S. FDA-approved nasally administered, needle-free, ready-to-use medication that can stop or reverse the effects of an opioid overdose.”

The liquid spray drug delivery technology platform provides dose accuracy and ease of administration. The single-shot unit-dose system incorporates a primeless feature and 360-degree orientation to offer the patient or caregiver ready-to-use convenience.

“Opioid overdose is responsible for the deaths of thousands of Americans in communities throughout the country, leaving a trail of devastation for friends and families,” said Seamus Mulligan, Chairman and CEO of Adapt Pharma. “NARCAN Nasal Spray makes naloxone readily available for emergency use by a friend, family member, or caregiver, as well as offering an alternative treatment option for first responders and healthcare providers. It gives new hope to those concerned about the potentially fatal effects of opioid overdose.”

Narcan contains naloxone which is an opioid antagonist. It is marketed in the U.S. for emergency treatment of known or suspected opioid overdose.

“The U.S is facing an unprecedented opioid overdose epidemic,” said Mulligan. “By making Narcan Nasal Spray available, we hope to increase everyone’s access to emergency treatments across the U.S.”

Click here to read more about the collaboration between Adapt Pharma and Aptar Pharma in Healthcare Packaging.